BCL2 interacting protein 3 pseudogene 13 (BNIP3P13)

BCL2 interacting protein 3 pseudogene 13 (BNIP3P13) is designated in genomic databases as a pseudogene of the BCL2 interacting protein 3 (BNIP3) gene family. Pseudogenes are stretches of DNA that resemble known genes but are generally non-functional, lacking the capacity to encode a functional protein product. There is no current evidence that BNIP3P13 encodes a protein, functions as a receptor, enzyme, or is otherwise a druggable therapeutic target. Virtually all literature and functional characterization relate to the actual BNIP3 gene, which is a pro-apoptotic protein involved in apoptosis, autophagy, and various diseases including cancer[1][2]. BNIP3P13 itself has not been implicated in disease, drug interactions, or clinical therapeutic strategies. True protein-coding BNIP3 (not the pseudogene) is a member of the BCL2 family with roles in cell death and autophagy, and has been associated with various cancers[1][2]. However, BNIP3P13 does not encode this protein. Pseudogenes are often named similarly to their functional gene counterparts but generally do not produce functional proteins or participate in physiological pathways unless they acquire a novel role (which is rare and not documented for BNIP3P13). There is no evidence in major biomedical literature, clinical databases, or drug databases of BNIP3P13 being a target for any known drug, functioning as a biomarker, or being involved in toxicity or efficacy concerns. In summary: BNIP3P13 is best classified as a pseudogene with no established biological, therapeutic, or diagnostic role. The correct, functional target would be BCL2 interacting protein 3 (BNIP3), not the pseudogene BNIP3P13[1][2].

Other names

BNIP3P13